#1 ACON Aclarion, Inc.    

 Here's WHY: In 2024, total spending on spine surgery in the U.S. alone was $134.5 billion. Aclarion has created a game changing technology to improve surgery success, from a

paltry 51% in the past, up to a magnificent 97%...

It's A.I. driven-- and a priceless advance in spinal care.

 We chose ACON at #1 previously, and it skyrocketed 300%+.

Since its return to our #1 it has risen from $6.20 to $8.19.

Acon is steadily surging now, up as much as $1.99/sh from our first report on it, and poised to explode upward. It's partially due to the newly announced 28 months ($32.64/sh) in cash on hand, USC, Univ of Miami, London Clinic, Texas Spine, & Louisiana Spine expansions. 

  Aclarion is quite potentially worth billions due to the $134.5 Billion U.S. spine surgery market alone.

Why? Nocsiscan saves Insurance companies 50% on spine surgery costs, and they need this kind of financial relief right now, and desperately. In addition, the U.K. is up and

running, paying Aclarion now...it's why their COH is up.

Australia was said to be next by CEO Ness.

Aclarion boasts an impressive list of working partnerships

in the medical field:

-Johns Hopkins 
-Scripps San Diego
-RadNet Network of NJ/NY
-Keck Medical Center of USC
-Texas Back Institute

-Northwestern Medicine
-Milwaukee's Advocate Aurora Research Institute
-Spine Institute of Louisiana
-Medical Imaging Center of Southern California
-Univ of Miami

A Report from the U.K.:

• The London Clinic has expanded its commercial engagement with Aclarion to increase access to Nociscan throughout Greater London.

• AXA, one of the largest private medical insurers in the UK, has started payer coverage for Nociscan, making it available to insured patients.

• Aviva, another major private medical insurer, has also approved Nociscan coverage, further expanding its accessibility.

• Vitality, a leading UK health insurer, has joined AXA and Aviva in covering Nociscan, meaning nearly 60% of privately insured patients in Greater London now have access to it.

 

 Aclarion also revealed a breakthrough with a unique and much needed A.I. spine surgery assistant, at the Selby Spine Conference in Utah, again in Tampa's conference in Feb,

again in April in Las Vegas, and in late June at the Spine Think Tank in Cabo. (Read about that here.) ​

  A 4 way "Buy Out bidding war" being imminent is rumored on Social Media and from inside sources--well-founded and logical chatter online is--based on recent defensive S.E.C. filings and states that 4 current affiliates of Aclarion are quite interested: 

-Scripps Health:

 A hospital network based in San Diego, which has annual revenue of $336+ million, and includes five acute-care hospitals, over 2,600 affiliated physicians, plus an extensive ambulatory care network.

-RadNet (RDNT), a leading provider of diagnostic imaging services, has a market cap of $3.735 billion and an enterprise value of $4.74 billion. RadNet just acquired iCAD, an A.I.-powered breast cancer screening company based in New Hampshire, and now has Aclarion, also an A.I. company,

next on its radar. This is why our $275/sh pt

 is quite possible with these 3-8 behemoths in play...

-Johns Hopkins, as the principal Nociscan Study investigator

is none other than the famous Dr. Nicholas Theodore of Johns Hopkins, himself.

MedTronic(MDT) -May be the winner here, as Aclarion's CEO was in their Management team, and the synergy is palpable!

  Rumours stated, likely leaked by insiders and posted online, is that $37/share would likely be the first bid, 5x the

current share price. The tiny float of 582K would not allow a direct stock buy out on the Market, as it would soar to $60-$120 quite fast.